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 1.  Introduction 
 Solid cancers (malignant tumors) are composed of cancer 
foci within a reactive stroma, which is populated by 
non-cancer cells such as fi broblasts and endothelial cells. 
The relative constituents vary, resulting in the architectural 
heterogeneity typical of cancer. This cancer-stromal relation-
ship is easy to observe histopathologically in the tissues. It is 
less easy to depict when imaging in vivo, either in patients 
or in animal models, as most imaging modalities (computer-
ized tomography, magnetic resonance and positive emission 
tomography) do not have the necessary resolution at the 
micrometer scale. Non-invasive imaging of the tumor micro-
architecture and detection of small disseminated disease foci 
away from the cancer mass boundaries would provide invalu-
able information that can directly inform treatment choices. 
 Nanoparticles (NPs) have the potential to act as tumor-
specifi c markers to enhance the resolution of current imaging 
platforms. Given their relative biologically inert qualities and 
stability, and unique physicochemical properties, GNPs are 
good contenders for enhancing imaging sensitivity. They are 
a reliable contrast medium for use with X-rays due to the DOI: 10.1002/smll.201400194
 In order to maximize the potential of nanoparticles (NPs) in cancer imaging and 
therapy, their mechanisms of interaction with host tissue need to be fully understood. 
NP uptake is known to be dramatically infl uenced by the tumor microenvironment, and 
an imaging platform that could replicate in vivo cellular conditions would make big 
strides in NP uptake studies. Here, a novel NP uptake platform consisting of a tissue-
engineered 3D in vitro cancer model (tumoroid), which mimics the microarchitecture 
of a solid cancer mass and stroma, is presented. As the tumoroid exhibits fundamental 
characteristics of solid cancer tissue and its cellular and biochemical parameters are 
controllable, it provides a real alternative to animal models. Furthermore, an X-ray 
fl uorescence imaging system is developed to demonstrate 3D imaging of GNPs and 
to determine uptake effi ciency within the tumoroid. This platform has implications for 
optimizing the targeted delivery of NPs to cells to benefi t cancer diagnostics and therapy. 
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high atomic number ( Z ). [ 1–3 ] This same attribute can be used 
to enhance the effects of X-ray radiotherapy [ 4–7 ] and proton 
radiotherapy. [ 8 ] Moreover, GNPs have a modifi able surface 
that can be used to increase solubility (to travel through 
the bloodstream) and enhance cell-specifi c uptake. [ 9 ] Addi-
tional coating with polyethylene glycol (PEG), sodium cit-
rate or heparin mitigates any toxicity, prevents initiation of 
blood coagulation and assists in evading the host immune 
system. [ 10 ] Further functionalization with cancer specifi c 
antibodies can enhance targeting and detection as reported 
using in vivo models with typical concentrations of the order 
of 0.01 mgNP/mL taken up by tumors—ten-fold greater 
compared to concentrations in the surrounding tissue. [ 11–14 ] 
In order to maximize their potential in cancer imaging, NP 
uptake mechanisms and impact of tumor environmental con-
ditions must be understood. 
 The cancer-stromal relationship infl uences how cancer 
cells uptake exogenous agents such as NPs. The majority of 
the research on biomarker imaging and NP uptake has been 
carried out in animal models. Although serving as a useful 
fi rst step, animal work does not always allow the delineation 
of the relevant mechanisms at the cellular level and has trans-
lated poorly to humans. The emergence of 3D in vitro cancer 
models [ 15 ] may provide a more direct and reliable method to 
test novel forms of biomarker-coupled imaging. In this paper 
we describe novel application of a 3D in vitro cancer model 
(tumoroid) capable of incorporating GNPs at typical concen-
trations achieved in vivo. The platform is based on a cancer 
model we have developed; previous molecular biology studies 
of the model have been presented to demonstrate biomim-
icry in terms of tumor growth and progression properties. [ 16 ] 
Here we present parallel work that demonstrates application 
of the model as a platform for NP uptake investigations, and 
as an imaging phantom with ability to inform development of 
NP imaging technology. It mimics tumor micro-composition, 
in terms of cell types and spatial positioning to allow specifi c 
investigations of NP uptake by cell types found within solid 
tumors. As a model, it has exciting potential for investigating 
cancer targeted imaging and therapy and can replace a con-
siderable proportion of work carried out in vivo. 
 Alongside the cellular model, a technique to measure 
GNP concentration and distribution is required for uptake 
investigations. The current gold standard technique for 
measuring GNP concentration is inductively coupled plasma 
atomic emission spectroscopy (ICP-AES). However, ICP-
AES is not an imaging technique, and digests cells in nitric 
acid at 110 °C which precludes further analysis. [ 17 ] As well 
as a clinical need for non-destructive measurement methods, 
there is also a requirement for a GNP imaging technology 
that is sensitive to suffi ciently low concentrations. Cur-
rent imaging technologies are lacking in this respect, with 
the lowest measurable concentration of 0.05 mgAu/mL 
using micro-computed tomography. [ 12 ] We have developed 
a novel non-destructive X-ray fl uorescence (XRF) tech-
nique that can be used to improve on NP imaging capa-
bilities lacking in current systems. This technique achieves 
sensitivity more than an order of magnitude greater than 
other reported techniques down to GNP concentrations of 
0.005 mgAu/mL. [ 18 ] XRF enables a greater penetration 
depth than optical techniques (being a higher energy 
modality) and offers potential for simultaneous imaging of 
multiple NP compositions. Our approach shows potential in 
both quantifi cation of and sensitivity to NP concentrations 
typically found in tumors. [ 18 ] 
 2.  Results 
 2.1.  GNP Uptake 
 The fi rst step of tumoroid production was to initiate GNP 
uptake within cell lines of each tumoroid component (artifi cial 
cancer mass: HT29 colorectal cancer cells, stromal component: 
3T3 murine fi broblasts). Uptake of GNPs of diameter 1.9 nm 
was achieved by both cell lines (incubation time 24 h) as dem-
onstrated by TEM ( Figure  1 ), and appeared to be through 
endocytosis (captured in  Figure  2 ). An incubation time of 24 h 
was found to give optimum GNP uptake in order to maximize 
GNP imaging signal per cell. It was observed that incubation 
times greater than 24 h were associated with signs of cell stress 
and apoptosis (up to 10% cell death at incubation time 48 h). 
X-ray microanalysis confi rmed gold presence within the cells; 
this involved a TEM technique that bombarded the sample 
with electrons and detected the emitted X-rays (the energy of 
emission being characteristic to elemental composition). 
 2.2.  GNP Uptake Measurement using X-Ray Fluorescence 
 Before complex tumoroids were constructed, uncompressed 
3D constructs were manufactured in order to test GNP 
uptake over a range of incubation doses. The following 
results enabled relation of GNP incubation dose with uptake 
concentrations for each cell line; this data was subsequently 
used to inform controlled engineering of GNP concentration 
within each tumoroid component (ACM and stroma). 
 2.2.1. Measured XRF Spectra 
 To confi rm sensitivity to gold the XRF system was used to 
obtain emission spectra for two 3D uncompressed HT29 
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 Figure 1.  TEM image of a 3T3 fi broblast (left) and an HT29 cancer cell 
(right) incubated with 1.9 nm GNPs (incubation time 24 h). The cells 
appear viable; the dark appearance of the cytoplasm indicates presence 
of ground substances and a healthy state; organelles required for healthy 
cell functioning are present (such as the nucleus, endoplasmic reticulum 
and mitochondria). GNPs (black round spheres) appear either dispersed 
or as aggregates, mostly encapsulated in cytoplasmic vesicles. 
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cellular constructs (incubated with 4 mgAu/mL and 
0 mgAu/mL (control);  Figure 3 a). Typical measurement 
times ranged from 40 min for high concentration samples to 
400 min for the lowest concentration. The cell samples incu-
bated with gold present a spectrum with the characteristic 
gold fl uorescence lines, compared with the control samples 
which showed no gold present. 
 2.2.2. Calibration Curve 
 XRF analysis was performed on a range 
of known GNP concentration solutions in 
order to determine the actual GNP con-
centration present in the 3D constructs. 
The resulting calibration curve ranged 
from 0.005 mgAu/mL to 0.03 mgAu/mL 
(Figure  3 b). 
 2.2.3. Gold Concentration per Sample 
 Figure  3 c displays the measured GNP con-
centration found for the 3T3 and HT29 
3D uncompressed constructs. Repeats at 
the incubation dose 4 mgAu/mL gave the 
same fi nal GNP concentration within meas-
urement error. The XRF signal from the 
sample incubated with 4 mgAu/mL was 
four times greater than that incubated at 
1 mgAu/mL (Figure 3c). TEM images quali-
tatively corroborated the XRF technique’s 
fi ndings that uptake was proportional to 
initial GNP dose. Attaining a known GNP 
uptake was shown to be repeatable and 
reproducible well within the standard 
errors of measurement. Percentage uptake 
of initial incubation GNP dose per million 
cells as measured by a non-destructive XRF 
technique was found to range between 
0.3–0.5% and 0.1–0.3% for the 3T3 and 
HT29 cell constructs respectively. An order 
of magnitude estimate of the number of 
GNPs taken up per cell was undertaken 
for the highest measured GNP uptake (the 
3T3 sample given an incubation dose of 
4 mgAu/mL) as follows. The mass of gold 
per cell was estimated: A GNP concentra-
tion of ≈0.015 mgAu/mL was measured for 
this sample using XRF analysis ( Figure 3c); 
cell number was normalized to 1 million 
cells per mL. This corresponds to 0.015 ngAu 
per cell. The mass of one 1.9 nm GNP was 
estimated: Each NP was assumed to be a 
solid sphere of gold of calculated volume 
4.2 nm 3 . The volume was multiplied by the 
density of gold (19.32 g/cm 3 ) to give an esti-
mated mass of 7 × 10 −11 ng per NP. For this 
sample we inferred from XRF emissions that 
≈2 × 10 8 GNPs were present per 3T3 cell. 
 2.3.  Tumoroid Production 
 We implemented a 3D in vitro tissue-engineering technique 
to create a 3D model that incorporates NP cellular uptake: 
where the basic premise was to create a dense artifi cial 
cancer mass (ACM) comprised of HT29 colorectal cancer 
cells set within a dense collagen scaffold, surrounded by 
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 Figure 2.  TEM image of the cell membrane surface of an HT29 cancer cell incubated with 
1.9 nm GNPs (incubation time 24 h). The image has captured each step of endocytosis: 
1) GNP-membrane interaction, 2) membrane invagination to take up GNPs in to the cell, and 
3) resulting endosome transports GNPs towards the lysosomes (4).
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uncompressed collagen populated by non-cancer cells, in this 
case fi broblasts to mimic cancer stroma. [ 19 ] 
 Successful manufacture of a 3D tumoroid (full construct 
dimensions 8 mm diameter, 18 mm height; ACM diameter 4 mm) 
was demonstrated with 0.7 × 10 6 HT29 cells pre-incubated with 
5 mgAu/mL for 24 h (compressed ACM) and 6.3 × 10 6 3T3 
fi broblasts pre-incubated with 2 mgAu/mL for 24 h (uncom-
pressed stromal component). The incubation doses were chosen 
to engineer an ACM GNP concentration of 0.02 mgAu/mL and 
GNP concentration ratios of 5:1 between the ACM and sur-
rounding stroma to resemble conditions achieved in vivo. The 
engineered GNP-loaded tumoroid is displayed in Figure  4 . 
 2.4. 3D  XRF Imaging of Tumoroid 
 3D XRF imaging was performed of several image slices of the 
tumoroid, with a partial reconstruction displayed in Figure  5 . 
All component details were clearly visible with a delineated 
ACM emitting at fi ve times more than the surrounding cel-
lular stroma. The image presented in Figure  5 was taken at 
the Diamond synchrotron source, UK. The log scale amplifi ed 
recognition of the tumor region (red corresponding to 
highest gold concentration), the surrounding background 
(green corresponding to a lower gold concentration) and the 
plastic container (blue corresponding to absence of gold) in 
which the tumoroid was set. A control sample with no GNP 
incubation yielded no gold signal and so the ACM could not 
be distinguished from the surround. 
 3.  Discussion 
 3.1.  Summary of Results 
 We have presented a 3D in vitro cancer model (tumoroid) 
that was successfully used as a platform 
to image GNP uptake and distribution at 
concentrations achieved in human tissue. 
The tumoroid was engineered to have 
distinct tumor and stromal compartments 
mimicking the microarchitecture of solid 
cancers and developed as a more control-
lable replacement to small-animal models 
in order to assess NP delivery to tissue 
under controlled conditions. 
 The uptake of 1.9 nm GNPs into the 
cells used for the uncompressed single 
cell type 3D constructs and the more 
complex tumoroids was passive and 
largely related to the cell surface area, 
with 3T3 cells being larger than HT29 
cells (data not shown). It is likely that 
this passive uptake was facilitated by pro-
tein adsorption on to the GNP surface 
resulting in a protein corona from serum 
proteins found in the growth medium, 
which brings them in prolonged contact 
with the cell membrane and promotes 
small 2014, 10, No. 19, 3954–3961
 Figure 3.  Quantitative XRF measurement of GNP concentration within 3D constructs. a) Measured spectra of 4 mgAu/mL GNP incubation dose 
uncompressed HT29 cellular construct and 0 mgAu/mL (control) acquired over 40 mins; b) Calibration curve relating XRF signal to GNP concentration. 
The XRF signal has been normalized to the Compton peak and acquisition time. [ 20 ] A weighted linear fi t (solid line) and boundary levels (dashed lines) 
are shown. The boundary levels were fi t to fully include 95% of the data points and their error bars; the latter calculated using Poisson statistics. 
Measurements were made over a range of known GNP concentration solutions; c) GNP concentrations measured in 3T3 and HT29 3D uncompressed cell-
populated collagen gel constructs over a range of initial incubation doses. The boundary levels of (b) were used to determine the error on each sample 
GNP concentration measurement, which was then added in quadrature to the error in the XRF measurement resulting from statistical fl uctuations.
 Figure 4.  Tumoroid consisting of an artifi cial cancer mass (ACM):stromal surrounding GNP 
concentration ratio 5:1, the ACM of approximate concentration 0.02 mgAu/mL. a) Microscopic 
appearance (TEM) of tumoroid photographed in (b). The boundary between ACM and stroma 
is evident as a difference in collagen density, the greatest difference in collagen greyscale 
mapped as a dashed line to estimate the cancer/stromal boundary; collagen is more dense 
within the ACM (above dashed line) and stromal collagen less dense (below dashed line). 
GNP containing vesicles are visible within the cells.
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endocytosis. [ 20 ] There is huge potential for active targeting 
through conjugation of the NPs to antibodies that target 
tumor biomarkers and provide functional information as 
to the cellular characteristics of the tumor; for example for 
use in mapping hypoxia. 
 Dose dependent uptake was demonstrated at incubation 
times of 24 h. Signs of cytotoxicity were observed for longer 
incubation time. However, evidence for the cytotoxicity of 
GNPs is equivocal and requires further study. [ 11,21,22 ] 
 To our knowledge, no other tissue engineered in vitro 
alternative exists as an imaging platform for research in to 
imaging biomarkers. Our construct is biomimetic in terms 
of cell composition and spatial orientation (cancer mass sur-
rounded by collagen matrix and stromal cells). In particular, 
by using plastic compression, we have increased the density 
of cell-seeded collagen type I hydrogels to ≈7% (w/v), which 
aims to approach densities found in vivo (generally accepted 
as >10%). Cell viability was retained in cells embedded in the 
scaffold during compression (results not shown); a previous 
study showed that the standard compression method results 
in only a 10% reduction in cell viability. [ 23 ] Using a tissue 
engineering approach allows a high degree of modulation 
and reproducibility which is needed to probe how NP uptake 
is infl uenced by controlled introduction of further cell types 
and incorporation of different matrix components according 
to designed spatial positioning within specifi c local matrix 
densities. To the authors’ knowledge, the latter and its impor-
tance in cell uptake behavior within tissues is not addressed 
by any other existing in vitro cancer model. 
 Furthermore we have presented a novel quantitative 
imaging module (XRF) that is sensitive to GNP concentration 
and distribution and can perform non-destructive imaging of 
bulk 3D samples, the latter imperative for NP uptake studies. 
To summarise the important novel charac-
teristics of our imager, achieved through it 
being purpose designed and custom built, 
we can now meet the needs of NP-imaging 
that are required by the community and 
yet to be met in the literature: i) sensitivity 
to low NP concentrations typically found 
in vivo (our system is an order of magni-
tude more sensitive to others reported, 
with a detection limit of 0.005 mgAu/mL), 
ii) ability to quantify NP concentration 
over a 3D matrix: our high energy tech-
nique can measure bulk 3D volumes at 
depth (1–2 cm) currently unachievable by 
NP imaging techniques, iii) contains 3D 
positional information of NPs (with spatial 
resolution better than other technologies 
due to implementation of polycapillary 
optics), iv) does not require destruction 
of the sample unlike gold standard TEM 
and ICP-AES. In addition the module 
has potential for multiparametric imaging 
(simultaneous measurement of multiple 
NP types). We used both XRF imaging 
and the reference standard of TEM to 
observe GNP uptake and distribution in 
our 3D tumoroids. The use of GNPs as a contrast agent ena-
bled micrometer scale tumor detail to be imaged as can be 
observed in Figure  5 . This result demonstrates clinical poten-
tial of GNP-XRF imaging; tumors are not homogeneous, 
regularly shaped tissues and as such require an imaging tech-
nique to fully characterise the cell types and distributions 
within them to fully inform therapy regimens. 
 Our XRF technique was used to perform an order of 
magnitude estimate of the number of GNPs taken up per cell. 
At the highest given GNP dose of 4 mgAu/mL we estimated 
that ≈2 × 10 8 GNPs were present per 3T3 cell. This number 
of NPs per cell is in keeping with previous reports; one study 
quantifi ed NP uptake per cell at a rate that was four orders 
of magnitude lower than our own (3000 per cell) for HeLa 
cells given an incubation dose four orders of magnitude 
lower (0.14 µgAu/mL) with 14 nm GNPs. [ 20 ] A different NP 
size, and GNP stabilized with sodium citrate and different 
cell lines renders the results not directly comparable, but 
indicates that our estimates of number of GNPs per cell is 
appropriate and accurate. 
 3.2.  Clinical Implications 
 We have demonstrated the ability of imaging micrometer 
scale tumor detail using GNPs as a contrast agent and an 
XRF technique sensitive to GNP concentration and distribu-
tion. This holds great potential in the development of plat-
form technology, which relates to: i) testing active targeting 
of GNPs to tumors for a range of tumor characteristics 
under controlled conditions using our model as a platform; 
NP XRF can be used to determine microstructural and func-
tional signals of a range of biomarkers within the tumoroids, 
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 Figure 5.  XRF image of three different cross sections of a tumoroid composed of an ACM 
and surrounding 3T3-embedded collagen gel with a challenging GNP concentration ratio 5:1 
between the ACM and surrounding. The blue-to-red colour scale presents gold concentration 
(red representing the highest gold concentration).
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ii) harvesting and growth of cancer cells from a patient 
within our tumoroids, we can test the tumor characteristics, 
signalling and response to therapies on a patient-by-patient 
basis, delivering potential for true personalized medicine, 
iii) the development of a higher energy XRF system for 
potential to work towards GNP XRF in vivo imaging of 
tumors to guide therapy; the possibility of clinical transla-
tion from synchrotron to bench-top source has been dem-
onstrated previously, [ 18 ] iv) the ability to map specifi c tumor 
characteristics such as hypoxia can be used to inform cancer 
therapy regimens, for example, radiotherapy dose escalation 
to hypoxic regions, and v) NP XRF imaging enables capa-
bility to detect small clusters of infi ltrating cancer cells com-
monly missed by current imaging modalities. 
 GNPs were selected in this study to demonstrate the con-
cept of our platform for nanoparticle uptake and imaging 
studies as they are widely used within the community due 
to their clinical viability and are heavily reported within the 
literature; however our uptake and imaging platform is not 
limited solely to gold and will be used in future studies for 
uptake investigation of a range of clinically relevant metallic 
nanoparticles. 
 3.3.  Future Research 
 This work provides the basic protocol for assessing biofunc-
tionalized NP uptake in 3D in vitro models through the 
development of tumoroids; we shall extend the current work, 
which involved NP uptake in monolayer cultures to investi-
gate the cellular uptake of NPs in 3D cultures to represent 
more realistic in vivo conditions representative of the clinical 
situation. We also aim to make the model more sophisticated 
in terms of adding fl ow components to simulate lymphatic 
drainage and vasculature leakage. 
 The tumoroids provide a more controllable replacement 
to small animal models in order to assess imaging and treat-
ment regimes under modifi able tumor and stromal conditions. 
For example, investigations of the dose enhancing power of 
GNPs in radiotherapy will be undertaken using the models. 
Tumoroid technology has the potential to escalate progress in 
NP applications in cancer imaging and provision of personal-
ized cancer therapy, providing a platform to inform targeted 
drug delivery and uptake, and to assess the effectiveness of 
therapy at the cellular level. We have been developing in 
parallel a model for investigations in to tumor growth and 
progression and for therapeutic screening. [ 16 ] This model has 
demonstrated the formation of a hypoxic core at the centre 
of the ACM and expression of vascular endothelial growth 
factor (VEGF) by cancer cells at the stromal boundary. The 
level of hypoxia is controllable and dependent on the cell and 
extracellular matrix (ECM) density. We aim to implement 
such tissue engineering strategies to investigate the effective-
ness of NPs targeted for hypoxia. We will also use the tumor-
oids to investigate multi-biomarker imaging where different 
molecular targeting biomarkers can be tagged to different 
element NPs each of which will give a specifi c XRF signal 
and allow the sophisticated mapping of disease or response 
to treatment. 
 4.  Conclusions 
 A 3D in vitro colorectal tumoroid, which mimics the micro-
architecture of solid cancers incorporating GNPs at typical 
concentrations achieved in vivo, was developed in order to 
provide a nanoparticle uptake platform in order to develop 
nanoparticle imaging and therapy studies under controlled, 
variable tumor and stromal conditions. 
 Production of the tumoroids involved two stages during 
their development: i) effecting GNP uptake in cells, and 
ii) embedding the cells in a 3D scaffold. The former stage was 
successfully achieved with relative ease, thought to be pas-
sively facilitated by protein adsorption on to the GNP sur-
face of serum proteins found in the growth media. Future 
work will look at different culture media to see if different 
protein corona on the surface of GNPs has an infl uence on 
cell uptake and warrants further investigation. Percentage 
uptake of initial incubation GNP dose per million cells was 
found to range between 0.3–0.5% and 0.1–0.3% for the 3T3 
and HT29 cell constructs respectively. In an in vivo situation 
tumor cells will take up more GNPs than healthy cells due 
to leaky tumor vasculature and poor lymphatic drainage at 
tumor sites. The differential uptake of GNPs between cancer 
and stromal cells may be improved through functionalisa-
tion using specifi c antibodies, growth factors, and targeting 
peptides to meet the overall eventual aim of this project in 
using GNPs as contrast agents to image the distribution of 
bio-parameters of a tumor. TEM images qualitatively cor-
roborated the XRF technique’s fi ndings that uptake was pro-
portional to initial GNP dose, and captured the nanoparticle 
internalisation process of endocytosis. 
 3D-XRF imaging successfully measured a challenging 
GNP concentration ratio of 5:1 between the ACM and 
stroma of the tumoroid and all component details could 
clearly be seen. The current model will be extended in the 
future from GNP incubation in 2D culture towards 3D cul-
ture incubation techniques. Here our aim is to mimic the 
tumor microenvironment through platform technology to 
determine how cell-cell communication, cell-ECM inter-
actions, ECM and cell density, and outside physical and 
mechanical forces found under physiological conditions 
such as shear stress and fl uid fl ow, will affect and infl uence 
the uptake of nanoparticles in cells, making use of the non-
destructive XRF imaging technique to map the time course 
of GNP distributions within the model, which will have 
direct implications in personalized medicine and patient 
healthcare. 
 5.  Experimental Section 
 Gold Nanoparticles : GNPs with a 1.9 nm gold core and water-
soluble organic shell (Aurovist, Nanoprobes Inc., USA) were sus-
pended in phosphate buffered saline (PBS) and/or cell culture 
media to form 10 mgAu/mL stock solution. GNP size quantifi cation 
of these commercially available GNPs was previously measured 
through TEM analysis and found to have a mean particle diameter 
of 2.2 ± 0.2 nm (≈70% of particles ranged between 1.5 nm and 
2.5 nm). [ 24 ] 
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 Cell Culture and GNP Incubation : The human colon adeno-
carcinoma cell line HT29 (passages [p]:30-42) and the mouse 
embryonic fi broblast cell line 3T3 (p:28-32) (ECACC, Sigma-Aldrich, 
Dorset, UK) were cultured routinely under aseptic humidifi ed con-
ditions at 37 °C in 5% CO 2 /95% air, in Hepes buffered Dulbecco’s 
Modifi ed Eagle Medium (DMEM plus 1000 mg glucose/L and 
 l -glutamine, Sigma-Aldrich); and supplemented with foetal calf 
serum (10% FCS, 5129, First Link UK Ltd, Birmingham UK) and 
penicillin/streptomycin (1% P/S, GIBCO, Invitrogen, Paisley UK). 
For GNP experiments, cells were grown in 25 cm 2 fl asks to 75% 
confl uence and incubated with GNPs (0.5–5 mgAu/mL) in order 
to i) relate GNP incubation concentration with cellular uptake 
concentration for each cell line, and ii) to inform engineering of 
tumoroids to allow control of GNP concentration in each compo-
nent (ACM and stroma). Incubation was performed under a range 
of incubation times up to 48 h, under routine conditions, to ascer-
tain an incubation time for optimized GNP uptake within the limits 
of cell viability. After incubation, a strict protocol was followed 
to ensure reproducibility and maximum cell harvesting. The cells 
were washed with PBS (2 × 3 min), PBS-EDTA (1 × 2 min) and enzy-
matically detached using 0.5 mL of 1 mg/mL Trypsin in PBS-EDTA 
(1 min). Cells were resuspended in 5 mL media, 50 µL were 
removed for counting (haemocytometer) and the remaining were 
centrifuged (400 g , 5 min). Cells were resuspended in a fi nal 
0.1 mL or 0.4 mL of media, as appropriate to be used for manufac-
turing of 3D in vitro constructs. 
 Manufacture of 3D Uncompressed Cellular Constructs : 3D 
tissue culture constructs were engineered using HT29 cancer cells 
and 3T3 fi broblasts. All cells had taken up GNPs. The formation of 
collagen type 1 lattices involves fi brillogenesis—a thermodynami-
cally driven fi bril aggregation following neutralization of native 
collagen solution. Resultant collagen hydrogels consist mainly 
(>99%) of water and are therefore of a much lower collagen 
density than that found in vivo. We mixed collagen type I (rat-
tail collagen type I, protein concentration 2.035 mg/mL in 0.6% 
acetic acid, First Link UK Ltd.) and minimum essential medium 
(MEM, 10X with Earle's Salts, without  l -glutamine, sodium bicar-
bonate, GIBCO 21430, Invitrogen) and adjusted the pH to 7-7.7 
(NaOH: 1  m , 5  m ), as judged by indicator colour change. GNP-
containing cells (either HT29 or 3T3) were immediately added 
and the mixture micro-pipetted to ensure even cell dispersion. 
Collagen:medium:cell volume ratios were 8:1:1. The mixture 
(1 mL) was transferred to a polypropylene container (inner/outer 
diameter 8/9 mm, height 45 mm, 1.5 mL volume, Nunc), and the 
gel allowed to set in a humidifi ed incubator, 5% CO2/95% air at 
37 °C for a minimum of 30 min. 
 Manufacture of Tumoroid : A 3D in vitro tissue-engineering 
technique was implemented to create a 3D model that enables 
NP cellular uptake: where the basic premise was to create a dense 
artifi cial cancer mass (ACM), surrounded by uncompressed col-
lagen populated by non-cancer cells, in this case fi broblasts 
to mimic cancer stroma. [ 19 ] Briefl y, for the ACM, collagen type I 
and minimum essential medium (MEM) were mixed and the pH 
adjusted to 7-7.7 (described above). GNP-containing HT29 cells 
were immediately added to the mixture using a micro-pipette, 
and poured into a cuboidal mould resting on a nylon mesh which 
was in turn placed on top of a 165 µm stainless steel mesh and 
absorbent paper and allowed to set into a gel at room temperature for 
30 mins. [ 19 ] The gel was compacted using a standard plastic 
compression protocol modifi ed from [ 18 ] (compression under a 
73.55 g load, for 5 mins). The gel was turned over and the pro-
cess repeated to reduce cell concentration gradients resulting from 
directional fl uid fl ow. This compression results in approximately a 
16–fold increase in collagen density compared to uncompressed 
gels giving a fi nal collagen density for the ACM of 6.7% (w/v). [ 25 ] 
Collagen:MEM:cell volume ratios were 8:1:1 with an overall, pre-
compression volume of 4 mL. The dense ACM cuboid gel was 
divided in to ≈4 mm segments and each segment nested into a 
1 mL uncompressed collagen gel populated with GNP-containing 
3T3 fi broblasts (prepared as above) before placing in the incu-
bator and allowed to set. Full construct dimensions were 8 mm in 
diameter, 18 mm in height, and an ACM diameter of 4 mm. The 
construct was incubated for at least 30 mins before fi xation with 
10% gluteraldehyde (in PBS) for 24 h at room temperature. The 
30 minute incubation times were not suffi cient for cell-mediated 
gel contraction, which habitually starts within a few hours of incu-
bation and can continue to over a week. [ 26 ] 
 Transmission Electron Microscopy (TEM) : Fixed 3D culture 
constructs were dissected using a scalpel blade in to cubes < 2 
mm in thickness, washed in PBS and postfi xed using 1% osmium 
tetroxide/1.5% potassium ferricyanide (BDH, Leicester, UK) for 
1.5 h; washed in distilled water and dehydrated through a 
degrading ethanol series (30% to 100%). They were then placed 
in 50% alcohol/50% Lemix epoxy resin (TAAB Laboratories Equip-
ment Ltd, Reading, UK) mixture overnight (18 h), and the following 
day infi ltrated with 100% Lemix resin for 2 d and fi nally embedded 
in fresh Lemix resin and polymerized at 70°C overnight (18 h). 
Ultrathin sections were cut using a diamond knife (Diatome) and 
collected on 300HS, 3.05 mm copper grids (Gilder). Sections were 
stained with saturated uranyl acetate in 50% ethanol (TAAB) for 
four minutes followed by Reynold's lead citrate for 5 min (BDH). 
Sections were viewed using a Philips CM120 TEM and photo-
graphed with an AMT Digital Camera (Deben UK). 
 X-Ray Fluorescence Technique : A technique based on inducing 
X-ray fl uorescence (XRF) in GNPs was developed to enable non-
destructive quantitative assessment of the GNPs incorporated 
into the 3D constructs. [ 18 ] Here we have extended this 1D meas-
urement technique to enable step and shoot 3D imaging of bulk 
samples. [ 27 ] The system comprised a laminar incident excitation 
X-ray beam to excite the GNPs to fl uoresce, in conjunction with an 
energy-resolving 10 mm 2 silicon drift detector (SDD) coupled to a 
slightly focusing polycapillary optic which allowed collection and 
3D mapping of fl uorescence emissions. [ 28,29 ] The magnitude of the 
XRF signal characteristic to gold was proportional to the concentra-
tion of GNPs in the measurement volume. To calibrate, 1 mL GNP 
solutions were used at 0.005–0.04 mgAu/mL; the concentration 
range covered the range of GNP concentrations retained by the cell 
preparations. 
 GNP Uptake Measurement using X-Ray Fluorescence : Cell cul-
tures (HT29, 3T3) were incubated with GNPs (0.5–4 mgAu/mL) 
for 24 h and used for manufacture of 1 mL 3D uncompressed 
cellular constructs (as above). A maximum of 5 × 10 6 cells/mL 
were embedded into the collagen gel. XRF measurement using a 
clinically available bench-top molybdenum X-ray tube was used to 
determine the internalized GNP uptake effi ciency over a range of 
concentrations. 
 XRF Imaging of Tumoroid : Measurements were made at 
the Diamond Light Source, Oxford, UK. The incident energy was 
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optimized for gold XRF excitation, set to 15 keV (above the edge for 
gold L-fl uorescence of 11.9 keV and 13.7 keV for Lα / Lβ 2 and Lβ 1 
fl uorescence respectively), a compromise between optimum exci-
tation and minimization of the impact of the Compton shoulder 
background on the gold fl uorescence line. The beam, sample 
centre and SDD-optic module were aligned. A CCD camera located 
behind the sample was used to monitor the beam-sample align-
ment. An ionization chamber was used to monitor beam intensity 
in order to normalize the data. The sample was then scanned in 
both the  x -,  y -, and  z -directions to build up a pixellated image. The 
full energy spectrum was obtained at each point. GNP images were 
reconstructed off-line by computing the integral counts under the 
gold  Lα and  Lβ fl uorescence peaks. 
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